Shake-up at GSK won’t placate investors
GSK has launched a radical shakeup of its operations, but that's unlikely to satisfy investors unhappy with the drugmaker's perennial underperformance.


Emma Walmsley (pictured), CEO of GlaxoSmithKline (GSK), has launched “the most radical shake-up” of the group in 20 years, says Hannah Boland in The Daily Telegraph. The plan is to spin off GSK’s consumer-healthcare arm, “which makes toothpaste and... painkillers”, and use the cash raised to boost sales at the core business, dubbed “new GSK”.
With several drugs about to lose patent protection, the dividend will be cut, with the money saved reinvested in “a hunt for new blockbuster drugs”. Walmsley is under increasing pressure, says Boland in The Sunday Times. Since 2017 she has “slashed” poorly performing drug programmes, revamped management and “pushed the drugmaker back into oncology”. But this has not satisfied investors irked by GSK’s “perennial underperformance”.
Some want new leadership, while the decision of activist fund Elliott Management to take a stake in GSK is another challenge to her authority. Those calling for “radical change” at GSK are likely to be disappointed by this latest “fudge”, says Lex in the Financial Times. Walmsley’s promise that GSK will “coalesce around core pharma” is undermined by the fact that even after the hived-off consumer unit is listed, GSK will retain up to 20% of the new company.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
This in turn “reduces the kitty earmarked for dealmaking and research and development”. While this “vacillating” is “understandable”, as blockbuster drugs “take a long time to come to market”, Walmsley’s plan won’t “quieten those calling for her resignation”.
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
Emerging markets boast top growth stocks at bargain prices
Opinion Lim Wen Loong, investment director at Ashoka WhiteOak Capital, selects three growth stocks where he’d put his money
-
Beware the bubble in bitcoin treasury companies
Bitcoin treasury companies are no longer coining it. Short this one, says Matthew Partridge
-
Emerging markets boast top-quality growth stocks at bargain prices
Opinion Lim Wen Loong, investment director at Ashoka WhiteOak Capital, selects three growth stocks where he’d put his money
-
Beware the bubble in bitcoin treasury companies
Bitcoin treasury companies are no longer coining it. Short this one, says Matthew Partridge
-
Klarna leads a financial revolution – should investors buy?
Klarna has ambitions to rewire the global payments system and has huge growth potential
-
New faces don’t solve old problems – why strategy also matters when it comes to investment trusts
Opinion Changing managers often fails to boost a trust’s performance, says Max King
-
How to profit from silver’s record rise
Silver often lets investors down, but there may now be room for further gains, says Dominic Frisby
-
Are venture-capital trusts worth investing in?
Venture-capital trusts are a tax-efficient way to invest in early-stage companies. But are they worth the risk?
-
'Investors should back the AI maximalists'
Polar Capital is bullish on AI and believe that the sector is far from being a bubble
-
Waiting for a UK REITs rally – is real estate poised for a rebound?
Investors are still cautious about UK REITs. Private equity is snapping them up. One view must be wrong, says Cris Sholto Heaton